Current Cost Research Articles

Health care costs in the United States by demographic characteristics and comorbidity status

Current real-world health care cost information is needed to project future expenditures and inform policy. We estimated adults' 2019 health care costs in the United States (US) by age, sex, race/ethnicity, geographic region, and comorbidity. We aggregated and summarized health care costs in 2021 US dollars using claims data derived from Optum's de-identified Clinformatics® Data Mart database, which includes inpatient, outpatient, and prescription claims for commercial and Medicare Advantage beneficiaries nationwide. A total of 9,227,901 adults were included in the analysis. The largest group represented was 71-75 years old (13%), female (53%), White (68%), received care in the South (41%), and had commercial health insurance (56%). There was a positive relationship between health care cost and age. Females had a 1.3-fold multiplicative increase in costs compared to males (95% CI 1.33-1.34). There were 92.5% of individuals who had health claims in the Northeast, 89.6% in the Midwest, 88.9% in the South, 77.1% in the West, and 12.7% with unknown geographic region. Patients with severe renal failure, heart failure, or metastatic cancer incurred the highest mean yearly costs ($139,844, $113,031, and $85,299, respectively). Metastatic cancer and severe renal failure were associated with a 5.3-fold multiplicative increase in costs compared with not having these conditions, after adjusting for potential confounders (95% CI, 5.26-5.41 and 4.98-5.16, respectively). We identified patient characteristics and medical conditions that are associated with high health care cost burden and could benefit from tailored interventions. We provided detailed cost estimates to aid health care modeling, cost projection, and cost-minimizing interventions.

Healthcare performance for patients with heart failure in Iran: addressing the tip of the iceberg.

Chronic diseases, such as heart failure with reduced ejection fraction (HFrEF), remain significant factors in the healthcare burden in Iran. Healthcare systems must have comprehensive data on the current usage, costs, and quality of care to tackle these challenges and formulate strategic plans effectively. The study included 209 patients with a mean age of 58 years (SD = 16.5) who met the inclusion criteria of having an ejection fraction of less than 40% and a confirmed diagnosis of HFrEF. This study used nationally representative data to assess the healthcare usage, costs, and quality of HFrEF management in Iran. The most used services were medication dispensing (76%) and outpatient visits (53%), while rehabilitation (3%) and homecare (2%) were used less frequently. The annual per-patient direct medical cost was $1,464, with $308 (21%) paid out-of-pocket (OOP). Hospitalization accounted for most of the total cost (68%), and pharmacy expenses comprised the largest portion of OOP payments (46%). Echocardiography was performed for 91.1% of patients upon admission. Only 71.6% of patients had arrangements for a cardiology visit within seven days following hospital discharge. Additionally, only 67.5% of patients received prescriptions for angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, and 85% were prescribed beta-blockers. Patients with heart failure in Iran face challenges in accessing adequate cardiac care, including a lack of care continuity and advanced cardiac services. The study provided an essential benchmark for future healthcare reform.

Costs Analysis of Kidney Transplantation in Spain: Differences Between Regional Health Services

Background: For our society, chronic kidney disease is a major public health problem associated with high mortality, morbidity, reduced quality of life and a progressive increase in health costs. The aim of this study was to analyze and compare the current cost of kidney transplantation (KT) and kidney–pancreas transplantation (KPT) among the different Regional Health Services (RHS) in Spain. Methods: A descriptive comparative study analyzing the public prices of RHS in Spain. The Official Gazette of the different communities was consulted, where the latest available order on this type of cost was sought. A descriptive analysis was made of the stipulated cost of the KT and KPT, for each degree of severity, RHS, year of publication and cost calculation method. Mean cost and standard deviation were calculated. Results: KT prices were found for 15 of the 18 RHS (83.33%). The average cost of KT in Spain was €33,926.53 ± 6950.053 (range from €23,140.37 in the Canary Islands to €48,205.75 in Catalonia). For KPT, costs were found for 5 of the 18 RHS (27.8%). The mean cost of KPT was €65,792.38 ± 11,273.12 (ranging from €49,418.81 in Navarra to €78,363.20 in Andalusia). Conclusions: There is a large variability in KT and KPT costs in Spain between RHS. Our study underlines the importance of adopting standardized and updated costing methods for KT and KPT.

Cost-effectiveness analysis of Tumor Treating Fields treatment in Chinese patients with metastatic non-small cell lung cancer.

The LUNAR trial demonstrated the significant efficacy and safety of Tumor Treating Fields (TTFields) plus standard-of-care (SOC) [immune checkpoint inhibitor (ICI) and docetaxel (DTX)] for patients with previously treated metastatic non-small cell lung cancer (mNSCLC). However, it remains uncertain as to whether the high costs are justified by the corresponding survival benefits. Here, the cost-effectiveness of using TTFields plus SOC for treating mNSCLC was evaluated from the perspective of the Chinese healthcare system. A Markov model with a 15-year time horizon was established and used to comparedeveloped to enable the simulation of treatment-associated costs and patient outcomes when comparing TTFields plus SOC to SOC alone. Primary outcomes for these analyses included total costs, life-years (LYs), quality-adjusted LYs (QALYs), and incremental cost-effectiveness ratio (ICER) values. The impact of paramere uncertainty on model outcomes was evaluated through sensitivity analyses. Additional subgroup and scenario analyses were also performed to extend these results. While TTFields plus SOC exhibited a $74,688 increase in total costs relative to SOC ($96,092 vs. $21,404), it was associated with 0.38 additional QALYs (1.08 vs. 0.82 QALYs) for an ICER of $284,490/QALY. This value exceeded the $35,983/QALY willingness-to-pay (WTP) threshold selected for these analyses by a wide margin. Relative to ICI and DTX treatment, the incremental costs of TTFields plus ICI and TTFields plus DTX were $78,115 and $71,307, respectively, with corresponding gains of 0.42 and 0.13 QALYs, yielding ICERs of $187,434/QALY, and $546,386/QALY. The parameter that most strongly impacted the results of these analyses was the cost of TTFields. The results indicated that given current treatment costs, TTFields plus SOC was insufficiently cost-effective in treating patients with mNSCLC in China, although TTFields plus ICI yields substantial health benefits.

Quantifying cost-savings in the treatment of neovascular age-related macular degeneration in Aotearoa New Zealand.

To estimate the cost-impact if faricimab were approved for the treatment of neovascular age-related macular degeneration (nAMD) in New Zealand. A retrospective, single-centre cost-analysis study. Data on intravitreal agent and injection intervals were obtained and statistically compared. Cost estimates were based on internal facility and publicly available data. The current costs of care were compared to two scenarios: one where all eyes receive faricimab, and another where eyes receiving aflibercept switch to faricimab. A total of 352 eyes from 292 patients were analysed. Present values locally over 10 years were estimated at -$6,776,340 for the first scenario and $5,015,922 for the second, releasing 252 and 176 hours of clinical time per year, respectively. Nationally, the savings extrapolated to -$187,925,737 and $139,104,706, respectively. The analysis indicates significant direct cost savings for the health sector and potential reductions in patient harm due to fewer injections. The approval of faricimab for the treatment of nAMD could result in substantial direct cost savings for the health sector. Additional benefits include reducing patient harm and improving ophthalmic health inequalities for Māori and Pacific peoples. Further research in diverse patient populations across multiple centres is needed to estimate the magnitude of cost savings more accurately. This study highlights the potential of faricimab to alleviate the treatment burden and provide a more sustainable healthcare option for nAMD in New Zealand, especially in cases of recalcitrant nAMD, if used in a tailored and patient-specific manner alongside the existing armamentarium of treatments.

Ground-breaking approach to enabling fully solar renewable energy communities

Renewable Energy Communities are an important strategy of the EU, to promote and optimize the distributed deployment of renewable generation systems. At current incentives and costs, RECs that share the energy produced by PV/battery systems are expected to take the lion's share of distributed generation. In this paper, we highlight some important critical issues in electric system management that could result from the deployment of RECs if PV/battery system generation cannot meet the entire community demand. Thus, we show how a flexible PV system (PV/battery systems able to provide firm/dispatchable generation) can be cost-effectively dimensioned to supply 24/365 96%–97 % of the demand of a residential users' community. We demonstrate that flexible PV systems of 1/10 MWp with 1.2/12 MWh of storage capacity can supply communities of 142/1420 residential users at a least production cost of 0.12/0.096 €/kWh. We further provide two business models based on power purchase agreement to demonstrate that, at these production costs, fully solar RECs are currently techno-economically feasible and provide mutual benefits to both flexible PV producers and REC members. Suitable virtual corporate PPAs can reduce the electric bill of the REC members by 11%–5% without requiring any investments and increase the producer incomes by 18%–22 %.

Application of the Clinical Outcomes, Healthcare Resource Utilization, and Related Costs Model in Chronic Obstructive Pulmonary Disease Patients

Introduction: The change in prevalence and management of chronic obstructive pulmonary disease (COPD) led to changes in outcomes and costs. We aimed to assess current clinical outcomes, resource utilisation, and costs in COPD. Methods: Retrospective, observational study of a cohort of consecutive COPD patients who visited the emergency department (ED) of a large tertiary hospital in 2018. The study measured baseline characteristics, 30-day and 1-year mortality, readmission, re-ED visit rates, and costs using the Clinical Outcomes, HEalthcare REsource utilisatioN, and relaTed costs (COHERENT) model, validated for heart failure. This model, featuring a colour graphic system, tracks time spent in different clinical situations (home, ED, hospital), considering vital status, healthcare resource use, and related costs. Results: In 2018, 2,384 patients with a primary COPD diagnosis visited the ED. The average age was 76 years, with 40% women. Observed mortality rates were 7.6% in-hospital, 8.5% at 30 days, and 23.4% at 1 year. The readmission rates were 9.9% and 36.1%, respectively. The cohort’s 1-year cost was approximately EUR 14.6 million (USD 15.95 million), with a median cost per patient of EUR 3,298 (USD 3,603.96). Hospitalisation incurred the highest costs, with initial hospitalisation and readmissions accounting for 44.7% and 42.6% of expenditures, respectively. Conclusion: One-year mortality and readmission rates for patients with COPD visiting the ED remain high with a significant economic impact on the health system. This burden justifies special programs to improve their care.

Recyclability level and quantity decisions of electronic manufacturers under four recycling systems of extended producer responsibility

Some electronic manufacturers and groups have left or are planning to leave the default recycling system that regulates their responsibilities for end-of-life (EoL) products. A legislative menu in the extended producer responsibility (EPR) framework allows manufacturers to choose the rate or cost model freely. In this paper, we model four potential recycling systems to study how two firms with brand differentiation should choose legislative models. We analyze the effect of take-back rate and brand differentiation on the firms’ equilibrium decisions, identify the condition in which firms leave the default plan, and further compare economic and environmental outcomes among all recycling systems. We find that only the cost system creates free-riding avenues because the current cost allocation mechanism by market shares does not concern the environmental contributions of members. We also find that the hybrid system (which includes rate-cost and cost-rate systems) provides higher design incentives than the basic case (which includes rate and cost systems), contrasting to the conventional wisdom in which the rate system has superior design incentives. Finally, our results demonstrate that the rate-cost system performs better economic and environmental benefits due to the perfect match between differentiated manufacturers and legislative models.

Radiographs are of limited use and low cost-effectiveness when combined with ultrasound for abdominal restaging in dogs with solid, soft tissue tumours.

The purposes of this study were to assess the frequency of detection of clinically relevant findings by abdominal radiographs and abdominal ultrasound during restaging of solid, soft tissue tumours in dogs and to determine the cost per clinically relevant finding for both modalities. The medical records of 159 dogs which underwent a total of 223 restaging episodes following a diagnosis of a solid, soft tissue tumour within, or with potential for metastasis to, the abdomen were reviewed. Data collected from the sample dogs were reviewed for clinically relevant findings, including local recurrence, lymph node or intra-abdominal metastasis, and other changes that would influence prognosis or management. The clinically relevant findings were compared between abdominal radiographs and abdominal ultrasound. The cost per clinically relevant finding was calculated per modality based on current hospital costs. Clinically relevant findings were observed in 158 restaging episodes. Ninety-two clinically relevant findings were detected with ultrasound alone, and 65 clinically relevant findings were detected with a combination of both modalities. Only one dog had a clinically relevant finding detected with radiographs alone. Findings were identified significantly more frequently with ultrasound than radiographs. Cost per clinically relevant finding was 495 USD (approx. 373 GBP/448 EUR) for abdominal radiographs and 323 USD (approx. 242 GBP/292 EUR) for abdominal ultrasound. Abdominal radiographs were of minimal use beyond abdominal ultrasound for restaging in this study, despite a higher cost per clinically relevant finding than abdominal ultrasound. This study does not support routine use of abdominal radiographs during routine restaging of solid, soft tissue tumours.

Development of a novel full thyristors hybrid DC circuit breaker combining vacuum and gas integrated series switch

In order to accelerate the fault current transfer rate of hybrid DC circuit breaker (HDCCB) and reduce the cost. A novel full thyristors HDCCB combining vacuum and gas integrated series switch is proposed in this paper, which accelerates the fault current transferred. Moreover, the breaking of higher current levels and lower cost by using the full thyristors to replace the IGBT and other power electronic (PE) devices are realized. The operation of proposed HDCCB is analyzed in detail, and the theoretical numerical model is derived. With the key parameters optimized in terms of the operation HDCCB, the breaking current capability and the effectiveness are verified by the simulation model. Based on this, preliminary tests from a developed low-power prototype are presented and verified the performance of the proposed novel HDCCB.

Willingness to pay for broadband: A case study of Wisconsin

As broadband expansion efforts in the U.S. continue with historic investments, consumer demand for residential broadband services is of first-order importance. Several past broadband willingness to pay studies estimate the value of broadband to be low, compared to the current national average cost of internet subscriptions being around $65 per month. Additional estimates of household's willingness to pay for broadband are needed to provide more insight into how much households value these services and what type of support would be most efficient in increasing broadband adoption to close the digital divide. These estimates are helpful for policymakers, internet service providers, and community leaders working on broadband subsidy programs, trying to bring ISPs to communities, and setting service prices. Using choice experiment data from a 2022 broadband survey in Wisconsin, I find households are willing to pay $45-$334 per month to go from not having internet at home to having speeds between 25 Mbps and 1,000 Mbps and are willing to pay $10-$38 for greater reliability, depending on household income level. While consumers are willing to pay more for speed than reliability, the value consumers place on speed is diminishing. Connection is valuable to people, but getting connected at a much faster speed is not seen as worth a lot more. These estimates suggest households place a high value on home internet and are willing to pay at least, if not more, than prices already available on the market in many places.

Fueling Costa Rica’s green hydrogen future: A financial roadmap for global leadership

This study evaluates the financial viability and scalability of green hydrogen production in Costa Rica, focusing on solar and wind energy. The research analyzes seven key provinces using Global Horizontal Irradiance (GHI) and wind speed data to assess energy potential. Monte Carlo simulations were employed to calculate the Net Present Value (NPV), hydrogen production costs, and economic sustainability over multiple project lifetimes. Guanacaste, with solar irradiance of 5.49 kWh/m2/day and wind speeds of 6.59 m/s, emerges as the most favorable region. The analysis reveals an NPV of $1,519.79 USD for onshore wind and $2,320.24 USD for offshore wind over 10 years. These values increase significantly for longer lifetimes, with 25-year NPVs of $3,687.40 USD for onshore wind and $5,890.72 USD for offshore wind, and 50-year NPVs reaching $7,456.21 USD and $11,560.38 USD, respectively. Hydrogen production costs are estimated at $49,696.75 USD from solar and $14,923.19 USD from wind energy. Despite its potential, high costs remain a challenge, requiring policy incentives, international cooperation, and green bonds to drive down costs and scale production. The study offers crucial insights for policymakers, investors, and researchers to support Costa Rica’s leadership in the global green hydrogen economy. Statement of SignificanceThe global shift toward renewable energy is critical for meeting decarbonization goals, and green hydrogen is emerging as a vital solution for sectors that are hard to electrify, such as transportation and heavy industry. However, the high cost of green hydrogen production poses a significant barrier to its widespread adoption. This study tackles the critical research problem of how to make green hydrogen economically viable by evaluating the potential of Costa Rica’s renewable energy resources—specifically solar PV and wind energy—to support large-scale hydrogen production.By integrating Monte Carlo simulations with region-specific financial analysis, this study provides a thorough assessment of hydrogen production costs and infrastructure requirements across Costa Rica’s provinces. The significance of this work lies in its localized approach, offering actionable insights into how a developing country with abundant renewable energy can position itself as a global leader in green hydrogen production. This research provides evidence that while current hydrogen production costs are higher than global targets, Costa Rica’s renewable resources present a strong foundation for future growth with the right policy interventions.The study’s findings have substantial implications for future research, policy, and investment strategies. By highlighting the financial and technological challenges, as well as offering potential solutions through international partnerships and innovative financing models, this research paves the way for Costa Rica and similar countries to contribute meaningfully to the global green hydrogen economy.

Dimensional Accuracy in 3D Printed Medical Models: A Follow-Up Study on SLA and SLS Technology

Background: With the rise of new 3D printers, assessing accuracy is crucial for obtaining the best results in patient care. Previous studies have shown that the highest accuracy is achieved with SLS printing technology; however, SLA printing technology has made significant improvements in recent years. Methods: In this study, a realistic anatomical model of a mandible and skull, a cutting guide for mandibular osteotomy, and a splint for orthognathic surgery were replicated five times each using two different 3D printing technologies: SLA and SLS. Results: The SLA group had a median trueness RMS value of 0.148 mm and a precision RMS value of 0.117 mm. The SLS group had a median trueness RMS value of 0.144 mm and a precision RMS value of 0.096 mm. There was no statistically significant difference in RMS values between SLS and SLA technologies regarding trueness. Regarding precision, however, the RMS values for SLS technology were significantly lower in the splint and cutting guide applications than those printed with SLA technology. Conclusions: Both 3D printing technologies produce modern models and applications with equally high dimensional accuracy. Considering current cost pressures experienced by hospitals, the lower-cost SLA 3D printer is a reliable choice for point-of-care 3D printing.

Cost of operating a human milk bank in the UK: a microcosting analysis

ObjectiveGlobally, demand for donor human milk (DHM) is increasing with WHO guidelines recommending DHM as the first line nutrition for premature infants in the absence or shortfall of maternal milk....

Analysis of the Current Situation of Cost Management and Control of Highway Construction Projects

The highway engineering process is complex, coupled with a relatively long construction period, hence requires increased coordination between participating units to prevent economic disputes and efficiency losses. The main body of the construction project needs to strengthen the management and control of funds. In this regard, this paper analyzes the importance of cost management in highway projects by clarifying and analyzing the current cost management status quo problems and causes. The highway engineering cost control strategy and implementation methods are summarized to provide references for improving the quality of highway engineering.

Cost-effective operation strategies to secure drinking water accompanied by low emissions by water safety plans

ABSTRACT Inadequate energy management leads to more emission exposure, which causes climate change, severe environmental contamination, and human health risks. Therefore, the World Health Organisation (WHO) monitors universal efforts to prevent emissions and encourages governments to develop industries to transform the green economy. During the current study, the energy and cost variation was observed through three years (2020, 2021, and 2022) at a surface water plant in southern Egypt. Consistent with applying operation strategies that met convenient standard operating procedures (SOPs) during 2021 and 2022. Energy consumption was reduced by 13% to 17%, and the cost decreased by 5% to 12% for 2021 and 2022, respectively. These energy and financial savings should be considered as an influence of the water safety plans (WSPs). Detrended correspondence analysis (DCA) was utilised to identify the mechanism of energy consumption and its impact on the cost during the study period. The finding proves that the energy and cost rise is related to increased water demand during the summer months, periodic/emergency maintenance, and comprehensive cleaning activities. WSPs were applied to control biological oxygen demand (BOD), chemical oxygen demand (COD), and oil and grease (O & G) that show increasing values than Egyptian law.

The pathway to delivering injectable CAB for HIV prevention: strategies from global PrEP leaders leveraging an adapted version of the Intervention Scalability Assessment Tool (ISAT)

BackgroundLonger-acting cabotegravir (CAB) is a novel, safe, and efficacious pre-exposure prophylaxis (PrEP) for HIV prevention. As we near a time for CAB scale-up, the experience of global leaders in PrEP research and implementation can be leveraged to identify optimal strategies for scaling and integrating CAB into existing PrEP infrastructure worldwide.MethodsWe recruited leaders of HIV prevention clinical trials and large PrEP programs through a combination of purposive and snowball sampling for participation in individual interviews. We conducted interviews using a semi-structured guide that compared CAB to oral PrEP and sought perspectives on barriers and strategies for CAB scale-up. Interviews were conducted virtually, audio recorded, and transcribed. We used thematic analysis, grounded in an adapted version of the Intervention Scalability Assessment Tool (ISAT), to identify critical elements for optimizing delivery of CAB.ResultsFrom October 2021 to April 2022, we interviewed 30 participants with extensive experience in PrEP research, care, and programming. Participants worked in all seven WHO regions and reported a median of 20 years working in HIV and 10 years in PrEP. Participants agreed that CAB was efficacious and discrete, therefore having the potential to address current concerns about oral PrEP adherence and stigma. Participants indicated direct and indirect costs for provider training, expansion of existing medical infrastructure, and the current medication cost of CAB as major concerns for roll out. The true cost to the end-user and health system were unknown. There were some conflicting strategies on how to best address product targeting, presentation of efficacy, and timing of product availability with scale-up. Some thought that targeting CAB for the general population could normalize PrEP and decrease stigma, while others thought that prioritizing key populations could optimize impact by targeting those with highest risk. Overall, participants emphasized that to ensure successful CAB scale-up, communities and stakeholders must be involved at every stage of planning and implementation.ConclusionsOur evaluation found that although there is a clear and urgent need for additional HIV PrEP options beyond daily oral PrEP, CAB scale-up must be thoughtful, flexible, and based in lessons learned from oral PrEP rollout.

BIM and orthogonal test methods to optimize the energy consumption of green buildings

The construction industry’s rapid growth significantly impacts energy consumption and environmental health. It is crucial to develop optimization strategies to enhance green building energy efficiency and encompass comprehensive analysis methods. This study aims to introduce and validate a novel framework for optimizing energy efficiency design in green buildings by integrating Building Information Modeling (BIM) technology, Life Cycle Cost (LCC) analysis, and orthogonal testing methods, focusing on enhancing energy efficiency and reducing life cycle costs. The optimization parameters for the building envelope are identified by analyzing energy consumption components and key green building factors. The orthogonal testing method was applied to streamline design options. Building Energy Consumption Simulation (BECS) software and LCC analysis tools were employed to calculate each optimized option’s total annual energy consumption and the current life cycle costs. Using the efficiency coefficient method, each optimization scheme’s energy consumption and economic indicators were thoroughly analyzed. The framework’s validity and applicability were confirmed through an empirical analysis of a campus green building case in Fujian Province, demonstrating that the optimized framework could reduce energy consumption by 4.85 kWh/m2 per year and lower costs by 38.89 Yuan/m2 compared to the reference building. The case study highlights the framework’s significant benefits in enhancing environmental performance and economic gains. The results provide critical parameter selection and offer scientific and technological support for the design of building energy efficiency, promoting optimization techniques and sustainable development within the construction industry.

313 Many farmers want a prediction of future performance, not necessarily breeding potential

Abstract High heritability is a characteristic of many performance traits in cattle translating to a relatively strong correlation between an (accurate) estimated breeding value for an animal and its (future) production potential. However, the broad sense heritability (i.e., numerator in the formula includes both additive and non-additive genetic variance) is often larger than the narrow sense heritability (i.e., numerator includes only the additive genetic variance) especially for low heritability traits like reproductive performance. Moreover, the repeatability of a trait can be greater again, the difference between the heritability and repeatability is the inclusion of a permanent environmental variance in the numerator. Accurate and pertinent omic-based animal-level features can contribute to an increase in narrow sense heritability owing to a possible reduction in the residual variance; such data can also provide insights into both non-additive genetic variance and the permanent environmental variance. Even at the level of the contemporary group, omic-level data from the likes of bulk blood/saliva/milk sample, can improve how systematic environmental effects are modeled in the mixed model equations thus also reducing the residual variance. The greater heritability will contribute to a strengthening of the correlation between future phenotypic performance potential and estimated additive genetic merit. Importantly, omic measures for individual animals can help predict the permanent environmental effect of that animal capturing the yet untapped contributor to phenotypic variance. Irrespective, predictions need to be replaced by prescriptions; end users are inundated with data yet crave actionable information. Animal breeders have a lush (pardon the pun!) history of distilling estimates of genetic merit for a plethora of traits into a single value per animal (i.e., breeding indexes); this is the first step in transitioning from predictions to prescriptions. Given the familiarity of end users with breeding indexes, the potential exists to develop production indexes to rank commercial animals on future expected performance taking cognizance of genetic and non-genetic effects. Such production indexes align well with the associated breeding index but where the estimates of genetic merit for the traits in question are replaced by estimates of production merit; these estimated production values are the sum of the additive genetic, non-additive genetic and permanent environmental effects. The weighting factors in the production indexes are more short-term using current costs and prices as opposed to breeding indexes which are longer term. In comparison with the breeding indexes, the production indexes can include ancillary information like gender, age, and month of calving/birth. Like breeding indexes, they are updated in real time. Examples of the application of genome-enabled production indexes are guides for valuing animals for purchase or culling.

Harnessing solar energy for sustainable green hydrogen production in Türkiye: Opportunities, and economic viability

Hydrogen emerges as a promising solution for Türkiye, offering opportunities to enhance renewable energy production and reduce greenhouse gas emissions. Türkiye has significant potential for green hydrogen production, leveraging its abundant renewable energy resources and lower installation costs for renewable energy-based power plants.This study assesses the impact of capital expenditure (CAPEX) on the Levelized Cost of Hydrogen (LCOH) in Türkiye, focusing on both current and projected costs. The LCOH ranges from $3.79/kgH2 to $5.11/kgH2 for low and high CAPEX scenarios, given Türkiye's solar electricity cost of $40.32/MWh in 2024. Looking ahead to 2035, achieving Türkiye's hydrogen cost target of $2.4/kgH2 will require reducing electricity costs to $31/MWh for low CAPEX and $15.3/MWh for high CAPEX. The current electricity cost of $40.3/MWh is significantly above these targets, highlighting the need for substantial technological advancements and cost-reduction strategies to meet future economic objectives for sustainable hydrogen production.